isopentyl-(4-propyl-phenyl)-ether

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: isopentyl-(4-propyl-phenyl)-ether
• 英文别名: 4-Isopentyloxy-1-propyl-benzol；Isopentyl-(4-propyl-phenyl)-aether；1-(3-Methylbutoxy)-4-propylbenzene；1-(3-methylbutoxy)-4-propylbenzene
• 化学式: C₁₄H₂₂O
• 分子量: 206.328
• InChiKey: DHVHFJCGATZZQA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 甲醇 、 钯 作用下， 生成 isopentyl-(4-propyl-phenyl)-ether
  参考文献：
  名称：

  Spaeth; Bruck, Chemische Berichte, 1938, vol. 71, p. 2708,2711

  摘要：

  DOI：

文献信息

• Peptide based inhibitors of Raf kinase protein dimerization and kinase activity
  申请人：UNIVERSITY OF SOUTH CAROLINA

  公开号：US11162083B2

  公开（公告）日：2021-11-02

  Herein are described peptide-based compositions for modifying Raf kinase protein Dimerization. These compositions, treatments, and methods of use are directed to peptides that display a binding affinity for the dimer interface of a Raf kinase protein, methods for modifying Raf kinase dimerization, and methods for inhibiting tumor growth. An embodiment of the disclosure is a peptide generated by modifying an ordered sequence chosen from SEQ ID NO: 1 which corresponds to amino acids 503-521 of B-Raf kinase. The peptides disclosed herein include a modification to an ordered sequence of amino acids derived from SEQ ID NO: 1 that can improve or otherwise alter binding affinity of the peptide to the dimer interface.

  本文描述了用于调节 Raf 激酶蛋白二聚化的基于肽的组合物。这些组合物、治疗方法和使用方法针对的是对 Raf 激酶蛋白的二聚体界面显示结合亲和力的多肽、修饰 Raf 激酶二聚化的方法和抑制肿瘤生长的方法。本公开的一个实施方案是通过修饰选自 SEQ ID NO: 1 的有序序列产生的多肽，该序列对应于 B-Raf 激酶的氨基酸 503-521。本文公开的多肽包括对来自 SEQ ID NO: 1 的氨基酸有序序列的修饰，该修饰可改善或以其它方式改变多肽与二聚体界面的结合亲和力。
• DESIGN AND OPTIMIZATION OF TYPE IV BRAF INHIBITORS FOR THE TREATMENT OF MELANOMA
  申请人：UNIVERSITY OF SOUTH CAROLINA

  公开号：US20220127585A1

  公开（公告）日：2022-04-28

  Inhibitory peptides for modifying RAF kinase protein dimerization are described. The peptides display a binding affinity for the dimer interface of a B-Raf, allowing for modification of RAF kinase dimerization, and inhibition of tumor growth. An embodiment of the disclosure is a peptide generated by modifying SEQ ID NO: 1, which corresponds to amino acids 503-521 of B-Raf kinase, e.g., cyclization, N-terminal capping, C-terminal capping, substitution of one or more amino acid residues, etc. The peptides disclosed herein include a modification to SEQ ID NO: 1 that can improve or otherwise alter binding affinity of the peptide to the dimer interface.